CBT has staged one of its sharpest recoveries in months, yet the Street is still not fully on board.
The stock gained 7.1% on the week to close at $84.53, extending a 13.3% rally over the past month and lifting the year-to-date gain to 27.6%. Much of the fuel came from a strong Q2 earnings print on May 5, which drove a one-day jump of 8.6% and a five-day follow-through of 11.4%. That's the kind of post-results reaction that forces a reassessment — and analysts obliged, with several upgrading their price targets inside a week.
The Street's response has been to raise targets while staying at arm's length on conviction. JP Morgan's Jeffrey Zekauskas lifted his target from $68 to $70 this morning (May 13) but kept the Underweight rating intact — the clearest signal that at least one influential voice still sees the stock as having run ahead of fair value, with the current price of $84.53 sitting 17% above that target. UBS lifted to $86 from $81 last week, and Mizuho moved to $80 from $75 — both Neutral. The consensus mean target is $82.20, fractionally below where the stock trades today, leaving the average analyst return potential at -3.2%. That's the tension this week: the fundamental print was good enough to spark target increases, but the rating upgrades did not follow.
Short positioning is retreating in the wake of that move. Short interest has fallen 5.6% on the week to 5.4% of the free float — roughly 2.85 million shares — after building steadily through late April and early May from around 2.6% of the float in early April. The pullback feels like tactical short-covering after the earnings pop, rather than a structural shift in bearish conviction. Borrow remains inexpensive at 0.46%, up just 1% on the week and 9.5% over the past month — nowhere near distressed territory. Availability is comfortable, with the lending market well short of any squeeze dynamic. Days to cover, at 9.5, is elevated and ranks in the 4th percentile of the universe, but with borrow loose and shorts already trimming, that metric reflects position size more than urgency.
Options traders are mildly more defensive than their recent baseline, but not alarmingly so. The put/call ratio climbed to 0.42, above the 20-day average of 0.35, putting it roughly 0.84 standard deviations above the mean. Against the 52-week range of 0.13 to 2.02, that's a modest skew — options positioning has nudged toward protection but has not signalled any pronounced bearish conviction. The RSI at 69.8 confirms the stock is approaching technically overbought territory after its recent run.
Valuation has re-rated meaningfully. The P/E multiple is now 13.0x, up 1.4 turns over the past 30 days, and price-to-book has risen 0.28 over the same period to 2.58x. The EV/EBITDA of 7.4x has actually compressed slightly, reflecting earnings growth outpacing the stock re-rate on that metric. The EV/EBIT factor rank is notably strong at the 85th percentile, suggesting the market is not yet paying an unreasonable price for operating income. The dividend score ranks at a perfect 100, and the forward yield of 2.3% provides some return floor.
Ownership is institutionally stable. BlackRock and Vanguard together hold nearly a quarter of shares outstanding, with both adding modestly in recent filings. American Century added 384,000 shares in April — the most active institutional mover of the top 15 holders. With the next earnings event currently unscheduled, the near-term focal point is whether consensus targets catch up to the current price, or whether the stock consolidates while analysts recalibrate. Peers offer mixed context: EMN fell 3.9% on the week, and NGVT dropped 7.2%, while DD and MTX each added around 2.5-2.6% — suggesting CBT's outperformance is partly idiosyncratic and partly sector-driven, with the chemicals space itself diverging sharply by name this week.
The gap between the JP Morgan $70 target and where the stock currently trades is worth tracking: if that view attracts more followers or the stock stalls here, short interest — now unwinding — may find fresh motivation to rebuild.
See the live data behind this article on ORTEX.
Open CBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
